Bristol-Myers Squibb to Present Data

Shares of Bristol-Myers Squibb were off 2% pre-market Thursday after the drugmaker said late Wednesday that more than 80 presentations will be made at the annual meeting of the American Society of Clinical Oncology in Chicago next month, which include its oncology compounds across 20 types of cancer. The company said first efficacy data for investigational anti-LAG-3 in combination with Opdivo in anti-PD-1/PD-L1 relapsed or refractory patients and for Opdivo in combination with epacadostat showcases next wave of cancer research approaches.

Moreover, Opdivo plus Yervoy data will be featured in 18 presentations across multiple tumor types, including advanced small cell lung cancer, melanoma and colorectal cancer.The presentations will feature data on the company’s oncology research portfolio, including monotherapy and combination studies of Opdivo and Yervoy as well as studies of Emplicity and Sprycel.

Leave a Comment